Physician profile
Treesa A Silver
NPI 1134421837
$3,871.59
in general payments reported to CMS, 2019-2025
31 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 99% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.06 · 2023: $997 · 2024: $1,358 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,813.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $736.01 | 2022-2025 | |
| Abbvie INC. | $494.67 | 2023-2025 | |
| Amgen INC. | $351.04 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $308.02 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $282.93 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $273.87 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $165.19 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.61 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $118.61 | 2023-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.06 | 2023-2024 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $90.49 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $87.18 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $79.69 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $72.15 | 2023-2025 | Shingrix, Bexsero, Pediarix |
| Sanofi Pasteur INC. | $69.64 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $59.45 | 2024-2025 | Rexulti |
| Lundbeck LLC | $53.36 | 2024-2025 | Rexulti |
| Coopersurgical, INC. | $49.56 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Dexcom, INC. | $43.12 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $40.75 | 2025 | Symbravo, Auvelity |
| Sanofi-Aventis U.S. LLC | $39.21 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $32.68 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $32.66 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.60 | 2025 | Caplyta |
| Almatica Pharma LLC | $30.62 | 2023 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $21.46 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.88 | 2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $15.58 | 2024 | Quviviq |
| Modernatx, INC. | $15.41 | 2023 | Moderna Covid-19 Vaccine |
| Xeris Pharmaceuticals, INC. | $14.84 | 2024 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $14.25 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Treesa Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.